Dovitinib (TKI258)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenoid Cystic Carcinoma
Conditions
Adenoid Cystic Carcinoma
Trial Timeline
Mar 1, 2012 → Dec 1, 2015
NCT ID
NCT01524692About Dovitinib (TKI258)
Dovitinib (TKI258) is a phase 2 stage product being developed by Novartis for Adenoid Cystic Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01524692. Target conditions include Adenoid Cystic Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01831726 | Phase 2 | Completed |
| NCT01524692 | Phase 2 | Completed |
| NCT01478373 | Phase 2 | Completed |
Competing Products
11 competing products in Adenoid Cystic Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab | Eisai | Phase 2 | 52 |
| P-Sam | AstraZeneca | Phase 2 | 52 |
| Cetuximab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| AG-013736 (AXITINIB) | Pfizer | Phase 2 | 51 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Mometasone Furoate nasal spray + Placebo | Organon | Phase 3 | 72 |
| mometasone furoate nasal spray | Organon | Approved | 80 |